Claim being checked · Version 1 · Reviewed
“Sermorelin was once FDA-approved.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Supported with scope. The reviewed evidence supports this exact statement only in the situation described below.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for Sermorelin.
01 · Answer
Supported with scope
FDA records document the former Geref approvals. FDA later found that safety or effectiveness was not the reason for withdrawal.
- What kind of evidence this is
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- What this answer covers
- Historical Geref products, not current compounded sermorelin. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Approval and status. Whether a specific product has an approval or another official status.
02 · Sources
Read the sources behind this answer
01Geref (sermorelin acetate) approval packageU.S. Food and Drug Administration · FDA review · 1991
Supports the scoped claim02FDA determination that Geref was not withdrawn for safety or effectivenessFederal Register · U.S. Food and Drug Administration · Regulatory · 2013
Supports the scoped claim
Supports the scoped claim02FDA determination that Geref was not withdrawn for safety or effectivenessFederal Register · U.S. Food and Drug Administration · Regulatory · 2013
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.